61 results about "Squamous Carcinomas" patented technology

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention discloses a computer-aided drug screening method, system or device based on FBXO2 and PKM2. The invention provides a brand-new method, system or equipment for screening oral squamous cell carcinoma treatment drugs based on FBXO2 and PKM2, provides a tool for new drug development and clinical application for treatment of oral squamous cell carcinoma, and has a wide application prospect.

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.

The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

This invention relates to the interdisciplinary field of cell biology, experimental oncology, and translational medicine, specifically to a cancer-associated fibroblast cell line, its construction method, and its applications. This invention fills the research gap in mouse-derived oral squamous cell carcinoma-associated fibroblast cell line models and provides a method for constructing such a cell line. Through the inverted adherent culture and enzymatic digestion methods of this invention, a mouse-derived oral squamous cell carcinoma-associated fibroblast cell line with a clear origin, high purity, and long-term phenotypic and functional stability can be obtained. This allows for the establishment of a cryopreservable and resuscitable mouse oral squamous cell carcinoma-associated fibroblast cell bank, providing technical support for research related to the tumor microenvironment and immunotherapy.

The application discloses a Campylobacter for treating oral squamous cell carcinoma and application thereof. It is found by the application that a Campylobacter showae strain has significant anti-tumor activity on a mouse model of oral squamous cell carcinoma, can significantly inhibit tumor growth, and promote the formation of tertiary lymphoid structures in oral squamous cell carcinoma. Therefore, the Campylobacter showae strain and a composition thereof can be used for preparing products for preventing, treating, adjuvant treating or prognosis nursing oral squamous cell carcinoma, and provide a new microbial intervention strategy for oral squamous cell carcinoma and related immunotherapy.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

The application belongs to the field of tumor molecular diagnosis and targeted therapy, and specifically finds lncRNA RP11-499F3.2 which is significantly highly expressed in head and neck cancer through bioinformatics analysis of TCGA data; it is verified through clinical samples that the expression level of RP11-499F3.2 in head and neck squamous cell carcinoma is significantly higher than that in paracancerous tissues, and is closely related to the clinical prognosis of patients with head and neck squamous cell carcinoma; it is found through functional experiments that high expression of RP11-499F3.2 can promote the in-vitro proliferation, migration and invasion of head and neck squamous cell carcinoma cells; meanwhile, it is also found that RP11-499F3.2 can promote the drug resistance of head and neck squamous cell carcinoma cells to cetuximab; the disclosed lncRNA RP11-499F3.2 helps to reveal the new pathogenesis of head and neck cancer, provides a new tumor marker for the prognosis monitoring of head and neck cancer, and provides a new idea for the clinical treatment of head and neck cancer.

The invention relates to a polyethylene glycol medicine as well as a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula I or pharmaceutically acceptable salt thereof, an intermediate compound as shown in a formula II-XX, a method for preparing the compound, and an application of the compound in tumor resistance. Biological tests show that the compound has a remarkable inhibition effect on tumors such as breast cancer, non-small cell lung cancer, melanoma, oral squamous cell carcinoma and osteosarcoma.

The present application belongs to the technical field of biological medicine, and particularly relates to Hermetia illucens extract, an extraction method thereof and application thereof in preventing and treating tumors. The present application extracts polar components from Hermetia illucens powder, and the obtained Hermetia illucens extract has a significantly better inhibitory activity on the proliferation of Cal27 human tongue squamous cell carcinoma cells, Colo205 human colorectal cancer cells and U87 MG human brain astrocytoma cells than the Hermetia illucens powder without separation under the same mass concentration. In animal experiments, the Hermetia illucens extract can significantly prolong the survival cycle of MOC-1 tongue squamous cell carcinoma mice, and has a significantly better treatment effect than the Hermetia illucens powder and is close to the positive drug cisplatin.

The invention discloses an application of a TNFRSF12A inhibitor in preparation of a medicine for treating oral squamous cell carcinoma. Based on single cell transcriptome data, oral squamous cell canceration related tissues are divided into four tissue ecological subtypes, and a tumor sample is divided into two subtypes ET3 and ET4. The ET3 subtype is a lymphocyte infiltration type, and shows CD8 + T cell infiltration, immune activation pathway activity enhancement and high expression of CD3, CD8A and PDCD1; the ET4 subtype is a lymphocyte rejection type, is enriched with COL1A1 + fibroblasts, and is accompanied by high expression of TNFRSF12A, COL1A1 and CD276. According to the application disclosed by the invention, the expression of the TNFRSF12A in the ET4 subtype is obviously improved, in-vivo experiments prove that knockout or blocking of the TNFRSF12A can promote lymphatic T cell infiltration and inhibit tumor growth, and a stronger inhibition effect is shown when the knockout or blocking of the TNFRSF12A is combined with an immune checkpoint inhibitor. The invention provides a system for typing oral squamous cell carcinoma.

This invention discloses a method and system for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma, belonging to the field of two-dimensional image processing technology for oral squamous cell carcinoma. It aims to improve the accuracy and stability of early screening for oral squamous cell carcinoma. The invention acquires oral image data, labels the acquired images according to pre-set classification standards to obtain training and testing sets; preprocesses the oral image data to obtain preprocessed training and testing sets; performs data augmentation on the oral image data in the training set to obtain a data-augmented training set; constructs an image feature extraction model based on a convolutional neural network; and trains the convolutional neural network-based image feature extraction model using supervised learning to obtain a trained convolutional neural network-based image feature extraction model for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma.

The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.

The application relates to application of FLVCR2-AS1 as a biomarker and therapeutic target of oral squamous cell carcinoma, and belongs to the technical field of biological medicine. The application provides application of FLVCR2-AS1 as a biomarker in preparation of a product for diagnosing oral squamous cell carcinoma, wherein the nucleotide sequence of the FLVCR2-AS1 is shown in SEQ ID NO:1. It is found and identified in the application that FLVCR2-AS1 is specifically lowly expressed in oral squamous cell carcinoma tissues and cell lines, and the expression level is significantly related to the prognosis of patients. Further research finds that overexpression of FLVCR2-AS1 can effectively inhibit the migration and invasion ability of oral squamous cell carcinoma cells. These results prove that FLVCR2-AS1 is a novel molecular target with clinical application potential for oral squamous cell carcinoma.

The application discloses application of a reagent for detecting FOXA2 in preparation of a kit for diagnosis or differentiation degree evaluation, prognosis evaluation of head and neck squamous cell carcinoma. The reagent comprises a primer pair for amplifying FOXA2, wherein the primer pair comprises an upstream primer with a nucleotide sequence as shown in SEQ ID NO. 1 and a downstream primer with a nucleotide sequence as shown in SEQ ID NO. 2. By using the kit, diagnosis, differentiation degree evaluation and prognosis evaluation of head and neck squamous cell carcinoma and oral squamous cell carcinoma can be effectively realized, and the kit has high accuracy and good repeatability.

The invention relates to a 3, 4, 5-trihydroxy phenylacetate compound and a preparation method and application thereof, the 3, 4, 5-trihydroxy phenylacetate compound belongs to a compound shown in a general formula I and a general formula II, R1, R2 and corresponding derivatives thereof can activate a copper death pathway mediated by endogenous copper ions, have an obvious anti-tumor effect, and have a stronger anti-tumor effect in chemotherapy of drug-resistant tumors. The tumors comprise melanoma, liver cancer, gastric cancer, breast cancer, oral squamous cell carcinoma and the like. The compound is a non-copper ion carrier compound with a brand new structure, induced copper death does not depend on exogenous copper ions, and endogenous copper ions are dissociated by reducing the content of glutathione which is a copper ion chelate in cells. The copper ions are further combined with microfilament skeleton related protein to cause disintegration of the microfilament skeleton, so that copper death is induced. The compound disclosed by the invention can be used as a potential lead compound for inducing endogenous copper ion mediated copper death for anti-tumor therapy.

The present application relates to a kind of microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma and its preparation method, belong to medical technical field.The microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma, including photosensitizer precursor, anesthetic and solvent, the mass final concentration of the photosensitizer precursor is 15-25 %, the mass final concentration of the anesthetic is 4-6 %, and the photosensitizer precursor is hydrochloric acid aminolevulinic acid.The microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma prepared by the present application adopts the mode of microdroplet injection, solves the three big problems of drug delivery, function preservation and pain control commonly faced in the treatment of different sensitive parts (face, hand, genital organ, tongue), enhances the practicability of the microdroplet photodynamic therapy compositions for treating skin and mucous membrane squamous cell carcinoma of the present application.

This invention belongs to the field of biomedical technology and provides the application of exosome-derived TRIM59 inhibitors in regulating macrophage M2 polarization and combating oral squamous cell carcinoma. The TRIM59 inhibitor uses exosomes derived from oral squamous cell carcinoma tissue as carriers, with the surface modified with the M2 macrophage-targeting molecule M2pep, internally loaded with TRIM59 inhibitors and KRT6B inhibitors, and loaded with STING pathway agonists. This invention relies on the microenvironment targeting and membrane surface targeting modification of tumor-derived exosomes to precisely deliver TRIM59 inhibitors and KRT6B inhibitors to M2 macrophages and tumor cells. By silencing TRIM59, the resistance of M2 macrophages to the STING pathway is relieved, forming a temporal synergistic effect of first unlocking and then activating with the STING agonist, driving macrophages to M1 polarization.

The invention provides application of an EGFR (epidermal growth factor receptor) inhibitor in preparation of a medicine for treating diseases mediated by the activity of a guanylate exchange factor (GEF) or jointly mediated by the activity of the guanylate exchange factor (GEF) and the activity of EGFR tyrosine kinase. The diseases are cancers selected from the following groups: lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, melanoma, leukemia and glioblastoma. Specifically, the invention discovers that EGFR has a GEF function for promoting activation of Ras homologous protein (Rhb) besides traditional tyrosine kinase activity, the function does not depend on the tyrosine kinase activity and plays a key role by depending on a glutamic acid residue at the 804th site on an EGFR molecule, the Rhb-GEF activity of EGFR causes allosteric activation of a mammal rapamycin target protein complex 1 (mTORC1), and the activity of the EGFR causes allosteric activation of the mammal rapamycin target protein complex 1 (mTORC1). The tumor growth is finally promoted.

The application discloses a human head and neck squamous cell carcinoma clinical diagnosis reagent, which is a reagent for detecting the expression amount of a human NCAPH gene. The expression level of the human NCAPH gene is negatively correlated with the clinical prognosis of human head and neck squamous cell carcinoma. Experimental results show that the expression of the human NCAPH gene in a human head and neck squamous cell carcinoma cell line is higher than that in normal nasopharyngeal epithelial cells. Knocking down the expression of the human NCAPH gene can significantly inhibit the proliferation and colony sphere formation ability of the head and neck squamous cell carcinoma cells. The application also provides a drug for inhibiting the expression of the human NCAPH gene or a NPIDP small peptide drug for inhibiting the expression of the human PD-L1 gene. The NPIDP small peptide drug is used on human head and neck squamous cell carcinoma cells, can significantly compete to block the combination of NCAPH and HIP1R, promote the degradation of the PD-L1 protein, and thus enhance the T cell killing effect. The application provides a new diagnosis and treatment drug for the treatment of human head and neck squamous cell carcinoma.

The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.

This invention provides an application of a circular RNA detection reagent and a circular RNA inhibitor, belonging to the field of biotechnology. Specifically, the circular RNA detection reagent provided by this invention is an hsa_circ_0008623 detection reagent, wherein the nucleotide sequence of hsa_circ_0008623 is shown in SEQ ID No. 1. This invention is the first to discover that hsa_circ_0008623 can serve as a diagnostic and therapeutic target for oral squamous cell carcinoma, providing new ideas for the early screening and therapeutic drug development of oral squamous cell carcinoma.

To provide a method for predicting cancerization of oral leukoplakia and a method for determining the presence or absence of invasion of oral squamous cell carcinoma.SOLUTION: Provided is a method for predicting the cancerous transformation of oral leukoplakia, including predicting that the oral leukoplakia will become cancerous if the level of CHI3L1 localized in the nucleus is higher than a reference value, but will not become cancerous if it is low compared to the reference value, in cells of diseased tissue obtained from a subject having the oral leukoplakia. Also, provided is a method for determining the presence or absence of invasive oral squamous cell carcinoma, including determining that the oral squamous cell carcinoma has not invaded if the level of CHI3L1 localized in the nucleus is higher than the reference value, but the oral squamous cell carcinoma has invaded if it is low compared to the reference value, in cells of diseased tissue obtained from a subject having the oral squamous cell carcinoma.SELECTED DRAWING: Figure 6

This invention provides a novel magnifying endoscopic grading method and system for superficial esophageal squamous cell carcinoma based on IPCL recognition, relating to the fields of medical image processing and endoscopic-assisted diagnosis. This invention acquires narrowband or blue light imaging frames, uses a transparent cap for scale calibration, performs vascular enhancement, threshold segmentation, and morphological opening and closing operations on the images, extracts the vascular skeleton and calculates roughness indices, and simultaneously performs connected component analysis and maximum diameter measurement on avascular and stretched regions. Grading is determined by combining preset thresholds across multiple image frames, outputting the grading results and recording key parameters, thus achieving objective, accurate, stable, and repeatable automatic grading of invasion depth.

A method and kit for estimating the presence of oral squamous cell carcinoma in a subject by analyzing the protein levels of EGFR, p53, B7H6, and PdL1 in a subject's sample.

Applicant provides herein methods for treating a patient having a pre-cancerous oral leukoplakia (LK) lesion or for delaying the progression of a pre-cancerous oral LK to oral squamous cell carcinoma. It also provides methods to identify patients that more likely to respond to a therapy comprising administration of an effective amount of an anti-PD-1 or anti-PD-L 1 therapy.

Provided herein are methods of treating advanced solid tumors in a subject in need thereof, for example, when the subject has advanced squamous cell carcinoma of the head and neck, colorectal cancer, non-small cell lung cancer, and transitional cell carcinoma of the bladder. Also provided herein are methods of treating blood cancers, such as acute myeloid leukemia, in a subject in need thereof.

The invention discloses an inactivated thallus for treating oral squamous cell carcinoma and application of the inactivated thallus. The invention discovers that the thermally inactivated Campylobacter concisus has obvious anti-tumor activity on an oral squamous cell carcinoma model mouse, can obviously inhibit tumor growth and promote formation of a three-level lymphatic structure in the oral squamous cell carcinoma, and has no obvious toxicity on other tissues of the whole body. Therefore, the thermally inactivated Campylobacter concisus and the composition thereof can be used for preparing medicines for treating the oral squamous cell carcinoma and functional products for increasing anti-tumor immune response and relieving cancer symptoms, and a new microbial intervention strategy is provided for the oral squamous cell carcinoma and related immunotherapy.

The present application relates to ligands targeted to epidermal growth factor receptor (EGFR) and compositions for use in treating tumors. Specifically, a ligand targeted to EGFR is disclosed. The ligand comprises a heavy chain variable domain and a light chain variable domain. The ligand may be selected from the group consisting of a single chain variable fragment, a fusion protein, a monoclonal antibody, and an antigen-binding fragment thereof. The ligand may be conjugated to a liposome or a nanoparticle that encapsulates at least one chemotherapeutic agent to form a ligand-targeted liposomal or nanoparticle drug. Also disclosed are conjugates and formulations for use in treating tumors such as squamous cell carcinoma of head and neck. A method for making a ligand-targeted liposomal drug is also disclosed. The drug may be a chemotherapeutic agent selected from the group consisting of doxorubicine and vinorelbine.